Patent Term Extension Application for VOYXACT® (sibeprenlimab-szsi), Patent No. 10,385,123 | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

FDA-2026-E-3826

Patent Term Extension Application for VOYXACT® (sibeprenlimab-szsi), Patent No. 10,385,123

Documents

Comments

Description

OPEN

Comment Period OpensApr 10, 2026

Type	Title	Posted	Comments	Status
Other	Letter from U. S. Patent and Trademark Office to FDA CDER	Apr 10, 2026	--

CDER

Patent Term Extension Application

Sterne, Kessler, Goldstein & Fox P.L.L.C

Visterra, Inc.

VOYXACT® (sibeprenlimab-szsi)

Patent No. 10,385,123

OPEN